Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Posted by Defense World Staff on Dec 18th, 2025

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Michael Benkowitz also recently made the following trade(s):

On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $478.58, for a total value of $10,768,050.00.
On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00.
On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $473.66, for a total value of $10,657,350.00.
On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $470.43, for a total value of $10,584,675.00.
On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $10,171,575.00.
On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00.
On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total transaction of $9,393,750.00.
On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00.
On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total transaction of $9,907,875.00.
On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $450.24, for a total transaction of $10,130,400.00.

United Therapeutics Trading Up 2.2%

Shares of NASDAQ:UTHR opened at $510.94 on Thursday. The stock has a market capitalization of $22.00 billion, a PE ratio of 19.36, a P/E/G ratio of 4.96 and a beta of 0.86. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $513.93. The firm has a fifty day moving average price of $460.85 and a 200 day moving average price of $378.34.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. The business’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the company earned $6.39 earnings per share. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a report on Monday, December 8th. Bank of America upped their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. HC Wainwright upped their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Cantor Fitzgerald raised their price target on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $505.00.

Get Our Latest Report on UTHR

Institutional Trading of United Therapeutics

Several large investors have recently made changes to their positions in the business. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics during the 2nd quarter valued at $29,000. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. SVB Wealth LLC acquired a new position in United Therapeutics during the first quarter worth $32,000. Finally, Wilmington Savings Fund Society FSB grew its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.